Neuron23 Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$96.5M
- Investors
-
14
Neuron23 General Information
Description
Developer of precision medicines designed to treat genetically defined neurological, immunological, and inflammatory diseases. The company offers human genetics-based drug discovery, biomarker development, machine learning technologies, artificial intelligence-driven research capabilities, and therapeutic development programs, enabling patients with neurodegenerative, neuroinflammatory, autoimmune, and inflammatory diseases to access targeted treatment approaches.
Contact Information
Website
www.neuron23.comCorporate Office
- 343 Oyster Point Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
Corporate Office
- 343 Oyster Point Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
Neuron23 Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series D) | 24-Jun-2025 | $96.5M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series C) | 30-Mar-2022 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 15-Dec-2020 | $80M | $113M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A) | 18-Oct-2018 | $33.5M | $33.5M | Completed | Stealth |
Neuron23 Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A-2 | 19,885,000 | $0.000100 | $0.08 | $1.03 | $1.03 | 1x | $1.03 | 7.23% |
| Series A-1 | 13,000,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 4.73% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Neuron23 Comparisons
Industry
Financing
Details
Neuron23 Competitors (5)
One of Neuron23’s 5 competitors is Intellia Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Casma Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA |
Neuron23 Patents
Neuron23 Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025264994-A1 | Predictive biomarkers and use thereof to treat parkinson's disease | Pending | 21-Jun-2024 | ||
| WO-2025194074-A1 | Kinase modulators and methods of use thereof | Pending | 15-Mar-2024 | ||
| WO-2025137541-A1 | Kinase modulators and methods of use thereof | Inactive | 22-Dec-2023 | ||
| AU-2024269632-A1 | Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2 | Pending | 11-May-2023 | ||
| EP-4709377-A2 | Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2 | Pending | 11-May-2023 | C12Q1/6883 |
Neuron23 Signals
Neuron23 Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Blue Owl Capital | Asset Manager | Minority | ||
| Chimera Capital | PE/Buyout | Minority | ||
| SoftBank Investment Advisers | Growth/Expansion | Minority | ||
| Acorn Bioventures | Venture Capital | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority |
Neuron23 FAQs
-
When was Neuron23 founded?
Neuron23 was founded in 2018.
-
Where is Neuron23 headquartered?
Neuron23 is headquartered in South San Francisco, CA.
-
What is the size of Neuron23?
Neuron23 has 27 total employees.
-
What industry is Neuron23 in?
Neuron23’s primary industry is Drug Discovery.
-
Is Neuron23 a private or public company?
Neuron23 is a Private company.
-
What is the current valuation of Neuron23?
The current valuation of Neuron23 is .
-
What is Neuron23’s current revenue?
The current revenue for Neuron23 is .
-
How much funding has Neuron23 raised over time?
Neuron23 has raised $310M.
-
Who are Neuron23’s investors?
Blue Owl Capital, Chimera Capital, SoftBank Investment Advisers, Acorn Bioventures, and Cowen Healthcare Investments are 5 of 14 investors who have invested in Neuron23.
-
Who are Neuron23’s competitors?
Intellia Therapeutics, Casma Therapeutics, Beam Therapeutics, Abeona Therapeutics, and Denali Therapeutics are competitors of Neuron23.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process